Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.61 |
| ▸ | MYC | P01106 | 8/20 | 0.52 |
| ▸ | BCL9 | O00512 | 5/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028170 | 0.92 | PPARA (0.61) | PPARAMYCBCL9CTNNB1ALDH1A1 | |
| SCHEMBL4030006 | 0.90 | PPARA (0.50) | PPARAMYCBCL9CTNNB1ALDH1A1 | |
| SCHEMBL4033047 | 0.85 | MYC (0.59) | MYCALDH1A1SMN1; SMN2LMNAHPGD | |
| SCHEMBL4032192 | 0.85 | BCL9 (0.63) | PPARAMYCBCL9CTNNB1 | |
| SCHEMBL4033182 | 0.85 | MYC (0.51) | PPARAMYCALDH1A1SMN1; SMN2POLB | |
| SCHEMBL5360497 | 0.82 | BCL9 (0.62) | PPARAMYCBCL9CTNNB1ALDH1A1 | |
| SCHEMBL4027831 | 0.82 | PPARA (0.50) | PPARAMYCBCL9CTNNB1ALDH1A1 | |
| SCHEMBL5360492 | 0.82 | BCL9 (0.62) | PPARAMYCBCL9CTNNB1ALDH1A1 | |
| SCHEMBL27634993 | 0.81 | PPARA (0.69) | PPARABCL9CTNNB1ALDH1A1POLB | |
| SCHEMBL27616063 | 0.81 | PPARA (0.69) | PPARABCL9CTNNB1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567493-B1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | PFIZER PROD INC (US) | 2009-03-18 | — | — | EP | disclosed |
| CN-100439337-C | Phenyl substituted piperidine compounds for use as PPAR activators | PFIZER PROD INC (US) | 2008-12-03 | — | — | CN | disclosed |
| US-20070281935-A1 | Use | PFIZER INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070232647-A1 | Use of Ppar Agonists to Treat Ruminants | GOETZE LEOPOLD F | 2007-10-04 | — | — | US | disclosed |
| US-20070191429-A1 | PPAR ACTIVATORS | PFIZER INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-7199243-B2 | Piperidine compounds useful as PPAR activators | PFIZER INC. (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1765320-A2 | USE OF PPAR AGONISTS TO TREAT RUMINANTS | Pfizer Products Incorporated (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1753426-A2 | RUMINANT TREATMENTS | Pfizer Products Incorporated (US) | 2007-02-21 | — | — | EP | disclosed |
| CN-1717389-A | Phenyl substituted piperidine compounds for use as PPAR activators | PFIZER PROD INC (US) | 2006-01-04 | — | — | CN | disclosed |
| WO-2005115389-A2 | SPECIFIC PPAR AGONISTS FOR TREATING NEGATIVE ENERGY BALANCE | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005115369-A2 | USE OF PPAR AGONISTS TO TREAT RUMINANTS | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| EP-1567493-A1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | Pfizer Products Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040157885-A1 | PPAR activators | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| WO-2004048334-A1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | PFIZER PRODUCTS INC. (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191429-A1 | PPAR ACTIVATORS | PPARA, PPARG, PPARD | PPARA 1/4885MYC 4374/4885BCL9 2684/4885 |
| US-20040157885-A1 | PPAR activators | PPARA, PPARG, PPARD | PPARA 1/4885MYC 4374/4885BCL9 2684/4885 |
| US-20070281935-A1 | Use | ALPP, CPT1A, PIGS | PPARA 700/4885MYC 1298/4885BCL9 3385/4885 |
| US-20070232647-A1 | Use of Ppar Agonists to Treat Ruminants | PPARG, PPARD, PPARA | PPARA 3/4885MYC 800/4885BCL9 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.